Navigation Links
Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
Date:6/2/2009

New Insights into the Prediction of IBD Using Serology Testing Also Presented

SAN DIEGO, June 2 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings regarding a correlation between an important serologic marker used in the detection of Crohn's disease and particular genetic markers in patients at risk for celiac disease. In an oral presentation yesterday at Digestive Disease Week (DDW) in Chicago, Prometheus reported a statistically significant correlation between antibodies to the flagellin CBir1 and HLA haplotypes DQ2.5 and DQ8 in a study of 5,406 patients at risk for celiac disease who are EMA positive. Blood and serum samples were analyzed using PROMETHEUS(R) Celiac PLUS and PROMETHEUS(R) IBD Serology 7 diagnostic tests.

"Genetic tests to rule out celiac disease are now readily available. However, few genetically predisposed individuals actually develop the disease, despite gluten ingestion, for reasons that are not well understood," said Dr. Michelle Pietzak, a Pediatric Gastroenterologist in the Division of Gastroenterology at the University of Southern California Keck School of Medicine. "The results from this study show that an overly aggressive immune response to particular bacteria in the intestine, as in Crohn's disease, may contribute to the inflammation seen in patients with celiac disease."

New Insights into IBD Serology Testing

Results from two additional studies regarding the prediction of inflammatory bowel disease (IBD) using serology testing were also presented yesterday at DDW. The first examined the consistency of biomarkers in patients who received multiple PROMETHEUS IBD Serology 7 tests within a two-year period. The overall rate of repeat testing ordered was only 2.2%. The results showed high concordance between the original and repeat tests; median changes in biomarker serum concentra
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
2. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
3. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
4. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
7. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
8. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
9. Spirus Medical Announces Complete Examinations of the Small Intestine by Physicians Using Endo-Ease(TM)
10. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
11. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 As health officials across the Midwest warn against ... in Michigan will offer free diagnostic ... Meijer pharmacists to administer tests and, in some cases, fill ... participating in the study. The Grand ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), ... that the United States Patent and Trademark Office has ... patent application directed to the fundamental technology involved in ... delivery systems. The allowable subject matter is directed to ...
... Aug. 3, 2011 Reportlinker.com announces ... is available in its catalogue: ... and Services Market 2011-2021 - what ... http://www.reportlinker.com/p0578544/Lyophilisation-for-Pharmaceuticals-Technology-and-Services-Market-2011-2021---what-are-the-revenue-prospects.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ...
Cached Medicine Technology:Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology 2Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology 3Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 13
(Date:4/18/2014)... have made a discovery that turns 160 years of ... material long known to be essential for the fast ... is not as ubiquitous as thought, according to a ... Harvard Stem Cell Institute (HSCI) and the University,s Department ... Professor Jeff Lichtman, of Harvard,s Department of Molecular and ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
... badly treated fractures are some of the reasons why ... often laid up, according to orthopaedic experts here. ... with many delicate and complicated surgeries being performed here ... at the All India Institute of Medical Sciences (AIIMS) ...
... eyes could reveal the status of our health and ... disease.// ,Conventional vision tests reveal eyesight abnormalities, such ... Rosen, of Rosen Eye Associates, Manchester, a test of ... heart disease, cancer and diabetes, thanks to its superior ...
... exposure to industrial chemicals is causing a ‘silent pandemic’ ... globe. ,This study was published on Tuesday ... 1-in-6 children and most of the cases are disorders ... that disorders like autism, attention deficit disorder, cerebral palsy ...
... advised to build a three-month stockpile of food, medicine and ... pandemic, a news report said Tuesday. ,An advisory ... in the former British colony urging them to prepare the ... ,It suggests stockpiling 4.5 litres of water per person per ...
... lower the risk of acquiring a sexually transmitted infection, ... ,The November issue of Pediatrics which reports ... of acquiring and spreading such infections by up to ... routine neonatal circumcision. ,This study is only ...
... getting heavier , but a new study by Statistics Canada has a ... pace as they did earlier. //Adults between 18-64 were monitored for ... showed that they have put on weight steadily , but during the ... ,This welcome news is thought to be due to the fact that ...
Cached Medicine News:Health News:Mismanagement of fractures a major concern, say experts 2Health News:Eye could reveal serious health disorder 2Health News:Brain disorders caused by Industrial chemicals 2Health News:Risk of STD Lowered with Circumcision 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: